SEC Filing Summary: PerkinElmer, Inc. (10-Q)
Business Context and Reporting Period
This Quarterly Report on Form 10-Q covers the period ended September 28, 2003. The registrant is PerkinElmer, Inc. (Note: The input metadata lists "REVVITY, INC.", but the filing text explicitly identifies the registrant as PerkinElmer, Inc.). The company operates through three strategic business units: Life and Analytical Sciences, Optoelectronics, and Fluid Sciences. The reporting period reflects the integration of the Life Sciences and Analytical Instruments businesses into a single segment.
Key Financial Metrics
| Metric | Three Months Ended Sep 28, 2003 | Nine Months Ended Sep 28, 2003 |
|---|---|---|
| Sales | $367.1 million | $1,102.7 million |
| Operating Income | $33.9 million | $83.2 million |
| Net Income (Continuing Ops) | $14.1 million | $28.2 million |
| Net Income (Total) | $14.3 million | $25.0 million |
| Earnings Per Share (Diluted) | $0.11 | $0.20 |
| Cash and Cash Equivalents | $141.3 million (Balance Sheet) | $141.3 million (Balance Sheet) |
| Operating Cash Flow | N/A | $89.6 million |
| Long-Term Debt | $564.7 million | $564.7 million |
| Short-Term Debt | $4.6 million | $4.6 million |
Material Changes vs. Prior Period
- Revenue Growth: Sales increased 0.3% in the quarter and 0.7% year-to-date compared to 2002, driven by foreign exchange rates (approx. 4-5% positive impact) and growth in environmental/chemical analysis and digital imaging products. These gains were offset by declines in pharmaceutical, genetic screening, and aerospace markets.
- Profitability Improvement: Operating income surged 103% in the quarter and 333% year-to-date. This was primarily due to significant cost reductions (SG&A down 10% in the quarter, 13% YTD) from headcount reductions and facility closures, alongside improved factory performance.
- Restructuring: The company recorded a net restructuring reversal of approximately $3.0 million for the nine months ended September 28, 2003, largely due to lower-than-expected severance payments from prior plans.
- Debt Reduction: The company fully retired its zero-coupon convertible debentures ($157.4 million accreted value) in August 2003 using escrow funds and available cash. Additionally, $50 million of term loan debt was prepaid.
- Discontinued Operations: The company completed the sale of a significant portion of its entertainment lighting business and abandoned remaining assets, recording a net loss of $1.5 million on the disposition.
Guidance, Outlook, and Risks
- Outlook: Management expects operations to continue generating sufficient cash to fund expenses, capital expenditures, and interest payments. Excess cash will be used for debt repayment. Capital expenditures for the fourth quarter are expected to be similar to the first three quarters, subject to economic conditions.
- Restructuring Timeline: Most remaining restructuring actions are expected to be settled in 2003, with European severance obligations extending to mid-2004 and certain lease obligations beyond Q2 2004.
- Risks and Contingencies:
- Legal Proceedings: The company is defending a class action lawsuit regarding alleged misleading statements about prospects (filed July 2002). The court denied the motion to dismiss in September 2003. The company cannot estimate potential losses.
- 9/11 Litigation: The company faces potential indemnification claims from L-3 Communications regarding the detection systems business sold in 2002, related to 9/11 litigation. Losses cannot be reasonably estimated.
- Market Cyclicality: Results are sensitive to downturns in pharmaceutical, semiconductor, and aerospace markets.
- Debt Covenants: The company must maintain specific financial ratios under its senior credit facility and 8 7/8% notes. Failure to comply could trigger an event of default.
Investor Verification Checklist
- Verify the status and potential financial impact of the class action lawsuit (Civil Action No. 02-11314 GAO) and the 9/11-related indemnification claims.
- Confirm the sustainability of cost savings from restructuring and integration, particularly regarding SG&A reductions.
- Monitor the company's compliance with debt covenants (leverage and coverage ratios) given the high debt load ($569.3 million outstanding).
- Assess the impact of foreign exchange rates on future revenue, as international sales represent over 50% of total sales.
- Review the timeline for the remaining restructuring cash outflows, specifically European severance and lease obligations.